Posts - Fight Prostate Cancer | HealthUnlocked

Fight Prostate Cancer

2,993 members•1,375 posts

Sort posts by:

Newsletter published!

As usual, I have sent my newsletter to the sibscribers. Someone made me notice that the complete articles on my site were not aligned with the articles...

As usual, I have sent my newsletter to the sibscribers. Someone made me notice ...

•1 day ago

Phase 1 ACCEL trial recruiting: AC-225-PSMA-62 for OLIGOMETASTATIC HSPC and mCRPC

I am not oligometastatic, dammit! But this could really be something worth trying! It is, at least from preclinical studies, a more targeted version of the...

I am not oligometastatic, dammit! But this could really be something worth tryin...

•3 days ago

ProstACT phase 3 trial started recruiting in the US

ProstACT Global Phase 3 trial (NCT04876651) for TLX591, a PSMA-targeted radioligand therapy, globally in 2023, with a recent U.S. rollout announced on February...

ProstACT Global Phase 3 trial (NCT04876651) for TLX591, a PSMA-targeted radiolig...

•4 days ago

Want to take advantage of all our features? Just log in!

or

Early but promising: Ok, let's talk about mRNA vaccines

Some company (ok I try to avoid company names here, but it feels unnatural!) has successfully tested its Smart mRNA technology, a new approach to cancer...

Some company (ok I try to avoid company names here, but it feels unnatural!) has...

•4 days ago

Lu-177 or Actinium 225

If you you had a choice between Lu-177 or Actinium 225 which one would you do. This is for advanced stage after chemotherapy has been exhausted.

If you you had a choice between Lu-177 or Actinium 225 which one would you do. T...

•5 days ago

AI strikes again

Because Demis Hassabis delivers... Google has introduced an AI co-scientist to assist biomedical researchers by generating hypotheses, identifying knowledge...

Because Demis Hassabis delivers... Google has introduced an AI co-scientist to ...

•6 days ago

UPDATE: HLD-0915 RIPTAC, phase 1 trial first patient dosed

The first patient was dosed yesterday! Let's keep an eye on this new approach!...

The first patient was dosed yesterday! Let's keep an eye on this new approach!.....

•6 days ago

Phase 1, recruiting soon, OncoACP3

Normally I do not post much about imaging unless it's already at the theranostic stage, but in this case, being an Italian trial and research (which means that...

Normally I do not post much about imaging unless it's already at the theranostic...

•7 days ago

Smoking never killed anybody...

...ok I am just joking, but sometimes it gets frustrating to see all observational, retrospective studies (and similar) being disregarded because they are not...

...ok I am just joking, but sometimes it gets frustrating to see all observation...

•8 days ago

Newsletter 8 is out

As usual! You can find the extended version of the cited studies on prostatewarriors.com and there is a section with the past newsletters as well!

As usual! You can find the extended version of the cited studies on prostatewarr...

•8 days ago

Be the first to reply

EVO 2, an AI that could change everything

Super powerful, open-source...dynamite especially if used together with AlphaFold...let me introduce you EVO 2 Evo 2 AI is transforming synthetic biology,...

Super powerful, open-source...dynamite especially if used together with AlphaFol...

•9 days ago

Phase 2: ENV105 to fight drug resistance

Because, time is what we need!!!! ENV105, a monoclonal antibody, is showing promise for treating castrate-resistant prostate cancer (CRPC) by targeting CD105,...

Because, time is what we need!!!! ENV105, a monoclonal antibody, is showing pro...

•10 days ago

Be the first to reply

MedPage Today coverage of the recent Genitourinary Cancers Symposium (GuCS) on February 13-15, 2025.

MedPage Today provides expert commentary on conferences and research on a full range of medical conditions. The following articles on research presented at the...

MedPage Today provides expert commentary on conferences and research on a full r...

•10 days ago

Be the first to reply

When everything else stops working this old med might prolong life a bit. Case study of Megestrol (MA)

“Finally, after disease progression during enzalutamide, we decided to start a new line of hormone therapy. In fact, considering age, PS, and patient’s will,...

“Finally, after disease progression during enzalutamide, we decided to start a n...

•10 days ago

Great update: 67Cu-SAR-bisPSMA gets fast tracked by FDA

And it looks like it is way more reliable than 177Lu... The FDA has granted Fast Track Designation to 67Cu-SAR-bisPSMA, a novel radiopharmaceutical therapy...

And it looks like it is way more reliable than 177Lu... The FDA has granted Fas...

•11 days ago

Preclinical: Injectable Paste Targets Bone Cancer and Metastases

Let's hope!!!! Researchers from Aston University and the Royal Orthopaedic Hospital have developed a gallium-doped bioglass injectable paste that eliminates...

Let's hope!!!! Researchers from Aston University and the Royal Orthopaedic Hosp...

•12 days ago

AI strikes again in drug repurposing (not yet PCa but very interesting)

It's not yet Prostate cancer related, but I love it. It is a company traded on Nasdaq, so we are not talking about 3 guys that could be erased by some big...

It's not yet Prostate cancer related, but I love it. It is a company traded on N...

•13 days ago

Be the first to reply

China’s medicines are surprising the world

Keytruda, a cancer-immunotherapy medicine, ranks among the most lucrative drugs ever sold. Since its launch in 2014 it has raked in over $130bn in sales for...

Keytruda, a cancer-immunotherapy medicine, ranks among the most lucrative drugs ...

•13 days ago

ASCO GU 2025: Phase 1 Trial - Combination Therapy Shows Promise for Advanced Prostate Cancer

Another arrow..... A new Phase 1 study suggests that combining Cabozantinib with Atezolizumab could improve outcomes for patients with metastatic...

Another arrow..... A new Phase 1 study suggests that combining Cabozantinib wit...

•14 days ago

ASCO GU 2025: factors that lead to a faster castrations resistance

With all the limits of a retrospective study (otherwise I might almost become depressed...) A real-world study of 41,379 prostate cancer patients found that...

With all the limits of a retrospective study (otherwise I might almost become de...

•14 days ago

ASCO GU 2025: continuous ADT performs (slightly) better than intermittent ADT

But, who am I to say if a 15% difference is small or not? A phase 3 analysis from the S9346 trial confirms that continuous ADT (CAD) is superior to...

But, who am I to say if a 15% difference is small or not? A phase 3 analysis fr...

•14 days ago

177Lu PSMA vs Cabazitaxel for mCRPC: real-world data

In a nutshell.... If you can get both, get both (median OS = 29.6 months) If you have to choose, choose 177Lu-PSMA (median OS 16.5 vs 14.7 months for...

In a nutshell.... If you can get both, get both (median OS = 29.6 months) If y...

•14 days ago

Be the first to reply

As usual Newsletter 7 is out

And if you have missed the previous ones, you can always go to the newsletters section on https://prostatewarriors.com Check in your SPAM folder in case you...

And if you have missed the previous ones, you can always go to the newsletters s...

•15 days ago

Be the first to reply

saffron and chamomile for depression, might also help fight PCa - three papers quoted

My own use of chamomile is mainly to help sleep. I cut into a chamomile tea bag and eat the contents washed down by a small amount of water. I don’t want to...

My own use of chamomile is mainly to help sleep. I cut into a chamomile tea bag...

•15 days ago

Be the first to reply

Protect Funding for Cancer Research

As of February 2025, the Administration plans to implement significant budget cuts—exceeding $4 billion annually—to research institutions, including those...

As of February 2025, the Administration plans to implement significant budget cu...

•16 days ago

ASCO Gu 2025: real world data confirms that undetectable PSA nadir is a strong predictor of outcomes

Real world seems to confirm clinical trial data in this case! A real-world study from the IRONMAN registry confirms that achieving an undetectable PSA nadir...

Real world seems to confirm clinical trial data in this case! A real-world stud...

•16 days ago

Skin Patches vs. Traditional Hormone Therapy: A New Option for Metastatic Prostate Cancer?

I feel like...we will soon be all moved to estradiol! A phase 2 study from the STAMPEDE trial found that transdermal estradiol (tE2) patches, when combined...

I feel like...we will soon be all moved to estradiol! A phase 2 study from the ...

•16 days ago

TALAPRO-2 final data: a win for BRCA+ mCRPC, less positive data for other HRR mutations (like my ATM)

Ok, now I would LOVE to see the same trial using the new parp inhibitor saruparib , which is considered waaaaay less toxic and more targeted compared to the...

Ok, now I would LOVE to see the same trial using the new parp inhibitor sarupari...

•16 days ago

ASCO GU 2025: impact of homologous recombination repair (HRR) gene mutations in metastatic hormone-sensitive prostate cancer (mHSPC)

A study on homologous recombination repair (HRR) gene mutations in metastatic hormone-sensitive prostate cancer (mHSPC) found different impacts based on the...

A study on homologous recombination repair (HRR) gene mutations in metastatic ho...

•17 days ago

Phase 1/2 clinical results: CBP-1018 for heavily pre treated mCRPC patients, promising!

A new clinical trial shows CBP-1018, an experimental bi-ligand–drug conjugate, could be a promising treatment for mCRPC, as presented at ASCO GU 2025. Among...

A new clinical trial shows CBP-1018, an experimental bi-ligand–drug conjugate, c...

•17 days ago

Be the first to reply

Write a post or ask a question

Search posts

Pinned Posts

This community is no longer actively moderated

Community Guidelines

Latest poll

Which of the following sentences best describes you?

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.

Archive

2025

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

2024

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2023

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022

Jan

Apr

May Jun Jul Aug Sep Oct Nov Dec

2021

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019

Feb

Mar

Apr May Jun Jul Aug Sep Oct Nov Dec

2018

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015

Feb

Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014

Jan

Feb

Apr

May

Jun

Jul Aug Sep Oct

Nov